Validity of the screener and opioid assessment for patients with pain-revised (SOAPP-R) in patients with cancer

Junaid T. Yasin, MPH; Amy E. Leader, DrPH, MPH; Alison Petok, MSW, MPH; Gregory Garber, MSW; Britainy Stephens, MSW; Brooke Worster, MD

doi:10.5055/jom.2019.0512

Authors

Junaid T. Yasin, MPH
Amy E. Leader, DrPH, MPH
Alison Petok, MSW, MPH
Gregory Garber, MSW
Britainy Stephens, MSW
Brooke Worster, MD

DOI:

https://doi.org/10.5055/jom.2019.0512

Keywords:

cancer, opioid, screening, SOAPP-R

Abstract

Objective: To determine the utility of the screener and opioid assessment for patients with pain-revised (SOAPP-R) for patients with cancer-related pain.

Design: The authors performed a retrospective analysis of cancer patients screened with the SOAPP-R. Opiate abuse was determined using a combination of urine drug screens and analysis of patients’ electronic medical records.

Setting/Patients: Patients who were seen at a palliative care clinic presenting with pain or needing an opioid prescription at an academic medical center with any type of cancer were screened using the SOAPP-R (N = 69).

Outcome measures: Aberrant opioid-related behavior was determined using a combination of provider notes and urine drug screens.

Results: A positive SOAPP-R score (≥18) was observed in 27 participants (39.1 percent). The sensitivity and specificity of the SOAPP-R in the study population was 0.75 and 0.80, respectively.

Conclusions: The SOAPP-R, in its current form, may have value in screening patients with cancer for substance abuse. Incorporation of the screening tool in palliative and oncology settings may help reduce opioid abuse in cancer patients.

Author Biographies

Junaid T. Yasin, MPH

College of Population Health, Thomas Jefferson University, College of Population health, Philadelphia, Pennsylvania

Amy E. Leader, DrPH, MPH

Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, College of Population health, Philadelphia, Pennsylvania

Alison Petok, MSW, MPH

Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

Gregory Garber, MSW

Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

Britainy Stephens, MSW

Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

Brooke Worster, MD

Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

References

Portenoy RK, Ahmed E: Principles of opioid use in cancer pain. J Clin Oncol. 2014; 32(16): 1662-1670.

World Health Organization: Cancer Pain Relief: With a Guide to Opioid Availability. Geneva, Switzerland: World Health Organization, 1996.

Starr TD, Rogak LJ, Passik SD: Substance abuse in cancer pain. Curr Pain Headache Rep. 2010; 14(4): 268-275.

Butler SF, Fernandez K, Benoit C, et al.: Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain. 2008; 9(4): 360-372.

Butler SF, Budman SH, Fernandez KC, et al.: Cross-validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R). J Addict Med. 2009; 3(2): 66.

Akbik H, Butler SF, Budman SH, et al.: Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP). J Pain Symptom Manage. 2006; 32(3): 287-293.

Butler SF, Budman SH, Fernandez K, et al.: Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004; 112(1): 65-75.

Koyyalagunta D, Bruera E, Aigner C, et al.: Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med. 2013; 14(5): 667-675.